wire - news in brief
Medicine - Oct 19
Novartis phase II GEOMETRY mono-1 trial of investigational medicine capmatinib (INC280) shows positive results in patients with MET mutated advanced NSCLC Phase II study efficacy data showed overall response rate of 72.0% and 39.1%, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping
Environment - Oct 18
According to the prevailing opinion, species-rich ecosystems are more stable against environmental disruptions such as drought, hot spells or pesticides.
Life Sciences - Oct 18
Graphene has been hailed as the material of the future. As yet, however, little is known about whether and how graphene affects our health if it gets into the body.
Category
Results 1 - 50 of 318.
Novartis announces presentation of new Lutathera NETTER-1 data
Novartis announces presentation of new Lutathera NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden Lutathera treatment was associated with a
Novartis announces presentation of new Lutathera NETTER-1 data at ESMO demonstrating significant improvement in PFS regardless of baseline liver tumor burden Lutathera treatment was associated with a
Architect Bernard Tschumi has donated the archives of his Bridge City project - developed for the City of Lausanne in 1988 - to EPFL.
Modifying a virtual environment in just a few clicks
Creating and modifying a virtual reality environment just got a lot easier thanks to software being released today by Imverse, an EPFL spin-off.
Creating and modifying a virtual reality environment just got a lot easier thanks to software being released today by Imverse, an EPFL spin-off.
Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx leadership in spondyloarthritis
Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) , In rheumatolo
Data from the MEASURE 1 and FUTURE 1 studies show rapid and long-lasting sustained improvement in the signs and symptoms of ankylosing spondylitis (AS) and psoriatic arthritis (PsA) , In rheumatolo
Empa and BeAM, a manufacturer of machines for metal 3D printing, are glad to announce an extensive research and development agreement.
EPFL scientists will soon be heading off to Antarctica, where they will spend four months collecting reams of meteorological data at Australia's Davis research station.
Novartis announces new data from the first direct head-to-head trial to demonstrate superior efficacy of Gilenya over Copaxone in patients with relapsing remitting multiple sclerosis
Topline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (glatiramer acetate) 20mg Gilenya 0.5mg is the first and only disease modifying therapy to show superiority in reducing relapses vs Copaxone in a controlled, head-to-head trial Treatment discontinuations were overall more common in the
Topline findings from ASSESS show adult relapsing remitting multiple sclerosis (RRMS) patients taking Gilenya (fingolimod) 0.5mg experienced significantly fewer relapses than patients on Copaxone (glatiramer acetate) 20mg Gilenya 0.5mg is the first and only disease modifying therapy to show superiority in reducing relapses vs Copaxone in a controlled, head-to-head trial Treatment discontinuations were overall more common in the
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or VOC) vs placebo VOCs are the most common, painful complication of sickle cell disease and the main reas
Novartis analysis shows crizanlizumab (SEG101) increased the number of patients free of sickle cell pain crises vs placebo during SUSTAIN study Data published in the American Journal of Hematology show more than twice as many patients taking crizanlizumab did not experience a disease-related pain crisis (also called vaso-occlusive crisis, or VOC) vs placebo VOCs are the most common, painful complication of sickle cell disease and the main reas
Summit in the field of Additive Manufacturing
Empa underscores its leading role in the exchange of knowledge in the field of Additive Manufacturing (AM).
Empa underscores its leading role in the exchange of knowledge in the field of Additive Manufacturing (AM).
Novartis announces FDA and EMA filing acceptance of siponimod, the first and only drug shown to meaningfully delay disability progression in typical SPMS patients
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of d
There is a critical need for safe and effective treatments for secondary progressive multiple sclerosis (SPMS) - a highly debilitating form of MS characterized by gradual, irreversible worsening of d
Even Small Gifts Boost Business
The offering of a gift - a sign of gratitude for a good business relationship, or a bribe? It's a fine line that is often hard to judge.
The offering of a gift - a sign of gratitude for a good business relationship, or a bribe? It's a fine line that is often hard to judge.
Sandoz Healthcare Access Challenge (HACk) returns, seeking digital solutions to local healthcare access challenges
Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year's competition expands to seek broader
Despite major advances in modern medicine, universal access to healthcare remains the largest unmet medical need Building on the inaugural Sandoz HACk, this year's competition expands to seek broader
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress Preliminary findings from Part 1 of the FIREFISH study show that infants with Type 1 SMA are meeting developmental milestones including sitting without support Preliminary data from Part 1 of the SUNFISH study show improvements in motor function in people with Type 2/3 SMA No drug-related safety findings leading to withdrawal in risdiplam
Roche announces new data for risdiplam in Spinal Muscular Atrophy (SMA) at the World Muscle Society Congress Preliminary findings from Part 1 of the FIREFISH study show that infants with Type 1 SMA are meeting developmental milestones including sitting without support Preliminary data from Part 1 of the SUNFISH study show improvements in motor function in people with Type 2/3 SMA No drug-related safety findings leading to withdrawal in risdiplam
Jacques Lévy has been awarded the 2018 Vautrin-Lud Prize, a geography award modeled on the Nobel Prize.
Novartis licenses three novel anti-infective programs to Boston Pharmaceuticals
Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria Agreement is part of Novartis strategy to partner with l
Clinical and pre-clinical stage programs focused on addressing growing need for new treatments against drug resistant Gram-negative bacteria Agreement is part of Novartis strategy to partner with l
Empa is expanding its Coating Competence Center (CCC) thanks to a new partnership in the field of printed electronics with US-based equipment manufacturer Optomec.
On September 30, 2016, the active phase of the ESA's Rosetta mission came to an end with the controlled crash landing of the probe on the surface of the comet Chury.
Fructose metabolism and noncommunicable diseases: recent findings and new research perspectives
Prof. Luc Tappy, Department of Physiology Fructose is a physiological nutrient which, when consumed in excess, may have adverse metabolic effects, mainly in the liver (hepatic insulin resistance and fat storage).
Prof. Luc Tappy, Department of Physiology Fructose is a physiological nutrient which, when consumed in excess, may have adverse metabolic effects, mainly in the liver (hepatic insulin resistance and fat storage).
French Recommendations for Sugar Intake in Adults: A Novel Approach Chosen by ANSES
Tappy L., Morio B., Azzout-Marniche D., Champ M., Gerber M., Houdart S., Mas E., Rizkalla S., Slama G., Mariotti F., Margaritis I..
Tappy L., Morio B., Azzout-Marniche D., Champ M., Gerber M., Houdart S., Mas E., Rizkalla S., Slama G., Mariotti F., Margaritis I..
The use of pesticides is still widespread in Swiss agriculture - and the resulting damage to humans and the environment is immense.
Smart transportation systems need smart governance
Two EPFL researchers have just published a book highlighting the need for cities to adopt adequate governance mechanisms for their transportation systems.
Two EPFL researchers have just published a book highlighting the need for cities to adopt adequate governance mechanisms for their transportation systems.
Roche’s investigational medicine entrectinib showed a durable response of more than two years in people with a specific type of lung cancer
Entrectinib reduced tumours in people with ROS1-positive non-small cell lung cancer (NSCLC), including those whose disease had spread to the central nervous system (CNS) Data will be submitted to glo
Entrectinib reduced tumours in people with ROS1-positive non-small cell lung cancer (NSCLC), including those whose disease had spread to the central nervous system (CNS) Data will be submitted to glo
» Comment on this page.
"Science Wire" gives access to latest science news from universities, research centers and R&D companies.Add this page to your bookmarks
